Navigation Links
Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
Date:7/27/2011

SAN FRANCISCO, July 27, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, August 4, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Friday, September 2, 2011. To access the conference call, follow these instructions:Dial: (877) 299-4454 (U.S.); (617) 597-5447(international)Passcode: 93854703 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Friday, September 2, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 53256804.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.  

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585, jruddock@nektar.com


'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
5. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
7. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
9. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
10. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 On March 28, the U.S. ... adult patients with relapsing forms of multiple sclerosis (MS) ... first drug approved by the FDA for PPMS. Ocrevus ... professional.  "Multiple sclerosis can have a ... Dunn , M.D., director of the Division of Neurology ...
(Date:3/29/2017)... March 29, 2017 FinancialBuzz.com News Commentary  ... The U.S. could see ... a new report published by New Frontier Data, the legal cannabis ... pace of cannabis legalization in the United States ... considered to be a major factor that drives growth in this ...
(Date:3/28/2017)... YORK , March 28, 2017 "Chemotherapy Induced Neutropenia ... overview of the disease and global market trends of the Chemotherapy ... States , Europe ( France ... , Spain , UK) and Japan ... (RoE) and rest of the world (RoW). The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the Microsoft Cloud expert, is ... Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating ... Ralph S. Northam and Mayor of Richmond Levar M. Stoney. , Founded in 2001, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, ... public to take the Diabetes Risk Test to find out if they are at ... World Airports will light up the evening sky by programming the LAX pylons the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property values, ... leader in the real estate valuation industry for more than 40 years. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... thyroid pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on ... answering common questions regarding thyroid function. , Dr. Izabella Wentz is a ...
(Date:3/28/2017)... ... 28, 2017 , ... Medforce Technologies, Inc., a leading provider ... has joined the National Association for Home Care and Hospice (NAHC), the largest ... dying Americans of all ages and the caregiver who provide them with in-home ...
Breaking Medicine News(10 mins):